Shots:

• The ongoing P-IIIb VISIBLE OLE study involves assessing of Entyvio (SC) in adult patients with UC or CD- following enrolment and participation in the VISIBLE 1 (UC) or VISIBLE 2 (CD) studies. Patients who completed the maintenance period up to 52wks. (randomized completers) or who achieved clinical response @14wks. (non-randomized 14wks. responders) after a third IV infusion @6wks.- received Entyvio (SC- 108mg- q2w)
• Interim analysis from VISIBLE OLE study showed long-term findings consistent with the known safety profile of vedolizumab with maintained rates of clinical remission and corticosteroid-free clinical remission
• Entyvio is the first maintenance biological therapy approved across the EU in both IV and SC formulations to treat moderately to severely active UC or CD. VISIBLE OLE results presented at UEG Week Virtual 2020 congress
  
   ­ Ref: Takeda | Image: Takeda